Regulus Therapeutics Inc (RGLS)

Etorro trading 970x250
Regulus Therapeutics Inc (RGLS) Logo

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 10628 Science Center Drive, San Diego, CA, United States, 92121

Regulus Therapeutics Inc News and around…

Latest news about Regulus Therapeutics Inc (RGLS) common stock and company :

Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit
01 Dec, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced a presentation at the first annual Rare & Genetic Kidney Disease Drug Development Summit.

Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity
30 Nov, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the closing of its previously announced private placement of equity. The Company received gross proceeds of approximately $34.6 million from the sale of 58,923,352 shares of the Company's common stock ("Common Stock") at a purchase price of $0.36 per share. In addition, the Company sold 3,725,720 s

Regulus Therapeutics Announces Private Placement of Equity
24 Nov, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The financing was led by the Federated Hermes Kaufmann Funds and New Enterprise Associates (NEA), with participation from oth

Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Regulus (RGLS) delivered earnings and revenue surprises of -42.86% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates
10 Nov, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call
03 Nov, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights for the quarter ended September 30, 2021 on Wednesday, November 10, 2021, after the U.S. financial markets close.

5 Penny Stocks To Buy For Under $1 On Webull Right Now
03 Nov, 2021 FinancialContent
Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for
28 Oct, 2021 Yahoo! Finance

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More
18 Oct, 2021 FinancialContent

Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have ...

50 Biggest Movers From Yesterday
14 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated ...

Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher
13 Oct, 2021 FinancialContent

Toward the end of trading Wednesday, the Dow traded up 0.06% to 34,398.86 while the NASDAQ rose 0.70% to 14,566.72. The S&P also ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Oct, 2021 FinancialContent

Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The ...

Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge
13 Oct, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded down 0.43% to 34,229.72 while the NASDAQ rose 0.40% to 14,524.02. The S&P also ...

40 Stocks Moving In Wednesday's Mid-Day Session
13 Oct, 2021 FinancialContent

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
13 Oct, 2021 FinancialContent

Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market ...

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
13 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
13 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're at the halfway point of the trading week and that has us checking in on the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

20 Stocks Moving in Wednesday's Pre-Market Session
13 Oct, 2021 FinancialContent

Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, ...

Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease
12 Oct, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an I

Top Biotech Penny Stocks to Watch With High Volume Right Now
08 Oct, 2021 FinancialContent
Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science
30 Sep, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that David Baltimore, Ph.D., a director of Regulus, is the recipient of the 2021 Lasker-Koshland Special Achievement Award in the category of Medical Science.

First Week of RGLS January 2024 Options Trading
15 Sep, 2021 FinancialContent

Investors in Regulus Therapeutics Inc (RGLS) saw new options begin trading this week, for the January 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 856 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright 23rd Annual Global Investment Conference: An on-demand webcast presentation will be available on Monday, September 13, 2021 at 7:00 a.m. ET.

Is Regulus Therapeutics (NASDAQ:RGLS) Using Too Much Debt?
06 Sep, 2021 Yahoo! Finance

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
02 Sep, 2021 FinancialContent

Upgrades For Okta Inc (NASDAQ:OKTA), Needham upgraded the previous rating of Hold to Buy. In the second quarter, Okta ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
17 Aug, 2021 FinancialContent

Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market ...

Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
10 Aug, 2021 Yahoo! Finance

Regulus (RGLS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Regulus Therapeutics Q2 Earnings
10 Aug, 2021 FinancialContent

Shares of Regulus Therapeutics (NASDAQ:RGLS) fellin after-market trading after the company reported Q2 results. Quarterly ...

Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates
10 Aug, 2021 Yahoo! Finance

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Regulus Therapeutics Inc (RGLS) is a NASDAQ Common Stock listed in , ,

970x250